One-year results of intravitreal bevacizumab as an adjunct to trabeculectomy for neovascular glaucoma in eyes with previous vitrectomy

Miki, Atsuya; Oshima, Yusuke; Otori, Yasumasa; Matsushita, Kazunobu; Nishida, Kohji

doi:10.1038/eye.2011.58

Cited by 9 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, it is difficult to perform IVB in vitrectomized eyes with NVG (patients 5, 12, and 13), because, as has already been demonstrated, injected bevacizumab is quickly washed away from a vitrectomized eye [ 35 ]. However, there is one report demonstrating that IVB before TLE might further improve the surgical success rate for NVG in previously vitrectomized eyes [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

25-Gauge Microincision Vitrectomy to Treat Vitreoretinal Disease in Glaucomatous Eyes after Trabeculectomy

Kunikata

Aizawa

Fuse

et al. 2014

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. To determine the feasibility of using 25-gauge microincision vitrectomy surgery (25GMIVS) to treat vitreoretinal disease in glaucomatous eyes which have previously undergone trabeculectomy (TLE). Methods. A consecutive, interventional case series. We performed 25GMIVS in 15 glaucomatous eyes that had undergone TLE. Follow-up period was 11.5 months. Results. 25GMIVS was successfully used and led to improvement in visual acuity (P < 0.01). We performed 25GMIVS for proliferative diabetic retinopathy with neovascular glaucoma in 53% of eyes (8 of 15). Although 3 eyes needed further TLE following 25GMIVS, final IOP was below 21 mmHg in all eyes except one eye (93%) and was comparable to pre-25GMIVS IOP (P = 0.20) without an increase in the number of glaucoma medications (P = 0.14). Conclusions. 25GMIVS is a feasible treatment for vitreoretinal disease in eyes with preexisting TLE, effective in both significantly improving BCVA and preserving the filtering bleb, while not excluding further glaucoma surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

25-Gauge Microincision Vitrectomy to Treat Vitreoretinal Disease in Glaucomatous Eyes after Trabeculectomy

Kunikata

Aizawa

Fuse

et al. 2014

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…There have been previous reports of effective anterior segment neovascularization regression after IVB injection in vitrectomized eyes. 28,29 There are some limitations to our study. First, the PK properties of human eyes are known to be different from that in rabbit eyes.…”

Section: -918mentioning

confidence: 99%

Pharmacokinetics of Intravitreally Injected Bevacizumab in Vitrectomized Eyes

Ahn

Kim

Woo

et al. 2013

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

Purpose: To compare the pharmacokinetics (PKs) of intravitreally injected bevacizumab in vitrectomized versus nonvitrectomized control rabbit eyes. Methods: Twenty-five-gauge pars plana vitrectomy without lensectomy was performed in 17 right rabbit eyes (V) and 18 nonvitrectomized right rabbit eyes served as controls (C). After 1.25 mg/0.05 mL intravitreal bevacizumab (IVB) injections, eyes were enucleated at 1 h, 1, 2, 5, 14, and 30 days after the injection and immediately frozen at -80°C. Bevacizumab concentrations were determined after separation of frozen vitreous and aqueous humor (AH) compartments using indirect enzyme-linked immunosorbent assay. Bevacizumab concentrationtime data were analyzed to obtain PK data. Results: Vitreous clearance of IVB consisted of 2 phases, the first fast distribution and second slow elimination phase. Clearance of IVB was accelerated in V eyes only during the first phase and not in the second phase. The vitreous concentration percent ratios between V and C eyes were 94.7% (1 h), 70.5% (1 day), 89.2% (2 days), 94.2% (5 days), 99.2% (14 days), and 79.1% (30 days). Overall vitreous half-lives were 6.99 and 7.06 days for V and C eyes, respectively (1.6-h difference). Conclusion: Overall IVB PKs in rabbit eyes after vitrectomy without lensectomy are not substantially different from nonvitrectomized control eyes.

show abstract

“…The tenth study, an ongoing RCT, is evaluating a single injection of aflibercept followed by observation with injections of aflibercept at eight week intervals (NCT01711879). Of the eight studies using bevacizumab, three were non-comparative case series (Costagliola 2008;Jonas 2010;Miki 2011), one was a historical cohort (Eid 2009), one was an RCT of people with primary or secondary open angle glaucoma (excluded people with NVG) (Sedghipour 2011), and three were RCTs excluded for other reasons Wittstrom 2012;Yazdani 2009).…”

Section: Description Of Studiesmentioning

confidence: 99%

“…Retrospective chart review of IVB; 14 participants with iris neovascularization and secondary angle-closure glaucoma treated with between one and three intravitreal injections of bevacizumab and followed for at least 4 months; no control group Miki 2011 Prospective pilot study of bevacizumab injections as an adjunct to trabeculectomy; 15 participants (15 eyes) with previous vitrectomy were treated with trabeculectomy with MMC plus IVB and were followed for 12 months; no control group…”

Section: Jonas 2010mentioning

confidence: 99%